Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic Leukemia

Clinical Cancer Research

Volumn 15, Issue 1, 2009, Pages 368-373

  Verstovsek, Srdan ^a   AyalewTefferi, ^b   Kantarjian, Hagop ^a   Manshouri, Taghi ^a   Luthra, Raja ^a   Pardanani, Animesh ^b   Quintás Cardama, Alfonso ^a   Ravandi, Farhad ^a   Ault, Pat ^a   Bueso Ramos, Carlos ^a   Cortes, Jorge E ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ANTIBIOTIC AGENT; CD52 ANTIGEN; CORTICOSTEROID; COTRIMOXAZOLE; CROMOGLYCATE DISODIUM; CYCLOSPORIN A; CYTARABINE; DASATINIB; DIPHENHYDRAMINE; FUROSEMIDE; GANCICLOVIR; HYDROCORTISONE; HYDROXYUREA; IMATINIB; METHOTREXATE; NILOTINIB; PARACETAMOL; PEGINTERFERON ALPHA; PREDNISONE; STEROID; THYMOCYTE ANTIBODY; VALACICLOVIR; VALGANCICLOVIR;

ADULT; ADVANCED CANCER; AGED; ANTIGEN EXPRESSION; ARTICLE; CHRONIC LEUKEMIA; CLINICAL ARTICLE; CYTOMEGALOVIRUS INFECTION; DOSAGE SCHEDULE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG RESPONSE; DYSPNEA; EOSINOPHIL; EOSINOPHIL COUNT; EOSINOPHILIA; EOSINOPHILIC LEUKEMIA; FEMALE; FEVER; HERPES SIMPLEX; HUMAN; HYPEREOSINOPHILIC SYNDROME; HYPOTENSION; LEUKEMIA RELAPSE; LYMPHOCYTOPENIA; LYMPHOMA; MAINTENANCE THERAPY; MALE; ORBIT CELLULITIS; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RIGOR; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; BONE MARROW; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION; EOSINOPHILS; FEMALE; HUMANS; HYPEREOSINOPHILIC SYNDROME; LEUKOCYTE COUNT; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 58949090059     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1302     Document Type: Article

References (16)

1. Chusid MJ, Dale DC, West BC, et al.The hypereosino- philic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore) 1975; 54:1 -27.
2. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008;22:14-22.
3. Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N EnglJ Med 2003;348: 1201 -14.
4. Tefferi A, Patnaik M, Pardanani A. Eosinophilia: secondary, clonal and idiopathic. Br J Haematol 2006; 133:468-92.
5. Lefebvre C, Bletry O, Degoulet P, et al. Prognostic factors of hypereosinophilic syndrome: study of 40 cases. Ann Med Interne (Paris) 1989;140:253-7.
6. Kalac M, Quintas-Cardama A, Vrhovac R, et al. A critical appraisal of conventional and investigational drug therapy in patients with hypereosinophilic syndrome and clonal eosinophilia. Cancer 2007;110:955-64.
7. Alinari L, Lapalombella R, Andritsos L, et al. Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia. Oncogene 2007;26:3644-53.
8. Eisner J, Hochstetter R, Spiekermann K, et al. Surface and mRNA expression of the CD52 antigen by human eosinophils but not by neutrophils. Blood 1996;88: 4684-93.
9. Pitini V, Teti D, Arrigo C, et al. Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome with abnormal T cells: a case report. Br J Haematol 2004:127:477.
10. Sefcick A, Sowter D, DasGupta E, et al. Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome. Br J Haematol 2004;124:558-9.
11. Nussenzveig RH, Swierczek SI, Jelinek J, et al. Polycythemia vera is not initiated by JAK2V617F mutation. Exp Hematol 2007;35:32-8.
12. Vega F, Medeiros LJ, Jones D, et al. A novel four- color PCR assay to assessT-cell receptor γ gene rearrangements in lymphoproliferative lesions. Am J Clin Pathol 2001;116:17-24.
13. Nguyen DD, Cao TM, Dugan K, et al. Cytomegalovirus viremia during Campath-1H therapy for relapsed and refractory chronic lymphocytic leukemia and prolymphocytic leukemia. Clin Lymphoma 2002;3: 105-10.
14. Jabbour E, Verstovsek S, Giles F, et al. Chlorodeox- yadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome. Cancer 2005; 104:541 -6.
15. O'Brien S, Ravandi F, RiehI T, etal.Valganciclovir prevents CMV reactivation in patients receiving alemtuzumab based therapy. Blood 2007;111:1816-9.
16. Rothenberg ME, Klion AD, Roufosse FE, et al. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med 2008;358: 1215-28.